Rigel Pharmaceuticals, Inc./$RIGL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Ticker
$RIGL
Sector
Primary listing
Employees
163
Headquarters
Website
RIGL Metrics
BasicAdvanced
$518M
5.32
$5.43
1.20
-
Price and volume
Market cap
$518M
Beta
1.2
52-week high
$43.72
52-week low
$15.50
Average daily volume
687K
Financial strength
Current ratio
2.024
Quick ratio
1.712
Long term debt to equity
46.581
Total debt to equity
74.504
Interest coverage (TTM)
13.51%
Profitability
EBITDA (TTM)
107.013
Gross margin (TTM)
82.79%
Net profit margin (TTM)
36.51%
Operating margin (TTM)
39.04%
Effective tax rate (TTM)
1.33%
Revenue per employee (TTM)
$1,640,000
Management effectiveness
Return on assets (TTM)
39.01%
Return on equity (TTM)
376.09%
Valuation
Price to earnings (TTM)
5.318
Price to revenue (TTM)
1.913
Price to book
6.33
Price to tangible book (TTM)
9.26
Price to free cash flow (TTM)
7.791
Free cash flow yield (TTM)
12.84%
Free cash flow per share (TTM)
3.709
Growth
Revenue change (TTM)
105.62%
Earnings per share change (TTM)
-767.67%
3-year revenue growth (CAGR)
45.77%
10-year revenue growth (CAGR)
32.88%
3-year earnings per share growth (CAGR)
3.02%
10-year earnings per share growth (CAGR)
-4.45%
Bulls say / Bears say
Rigel’s net product sales in Q2 2025 jumped 76% year-over-year to $58.9 million, driven by strong demand for TAVALISSE, GAVRETO, and REZLIDHIA (PR Newswire)
The company raised its 2025 total revenue guidance to $270–280 million (up from $200–210 million), reflecting confidence in sustained commercial growth (PR Newswire)
Rigel completed enrollment of the dose escalation phase of its Phase 1b trial for R289, positioning it for upcoming data readouts and dose expansion in H2 2025 (PR Newswire)
Q2 results include $40 million in one-time, non-cash contract revenue from the Lilly opt-out, which inflates income and may not be repeated in future periods (PR Newswire)
The pipeline is currently anchored by only one mid-stage asset (R289 in Phase 1b), leaving near-term growth dependent on a single early-stage program and increasing clinical risk (PR Newswire)
Rigel cautions in its Q1 2025 10-Q that potential ANDA filings for its products (e.g., TAVALISSE) could lead to generic competition and materially harm product sales (SEC)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
RIGL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rigel Pharmaceuticals, Inc. stock?
Rigel Pharmaceuticals, Inc. (RIGL) has a market cap of $518M as of October 07, 2025.
What is the P/E ratio for Rigel Pharmaceuticals, Inc. stock?
The price to earnings (P/E) ratio for Rigel Pharmaceuticals, Inc. (RIGL) stock is 5.32 as of October 07, 2025.
Does Rigel Pharmaceuticals, Inc. stock pay dividends?
No, Rigel Pharmaceuticals, Inc. (RIGL) stock does not pay dividends to its shareholders as of October 07, 2025.
When is the next Rigel Pharmaceuticals, Inc. dividend payment date?
Rigel Pharmaceuticals, Inc. (RIGL) stock does not pay dividends to its shareholders.
What is the beta indicator for Rigel Pharmaceuticals, Inc.?
Rigel Pharmaceuticals, Inc. (RIGL) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.